AzTrials
AzTrials

Quality Evaluation System for ColonoscopyNCT04610177

Prospective Multicenter Study of Artificial Intelligence-assisted Quality Evaluation System for Colonoscopy

An observational study of Quality Evaluation System for Colonoscopy, run by Renmin Hospital of Wuhan University at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The quality control index based on artificial intelligence is put forward to monitor the quality of enteroscopy. And we will verify the correlation between the detection rate of adenomas and the percentage of endoscopic overspeed mirrors, the number of times of no-return/successful return, the real-time Bowel… Read more about this study

Who is it for?
Ages 50 to 80 years
How many people
5,813 participants
Where
1 siteChina
Study dates
2 Jun 2020to 16 Dec 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: A total of 5813 patients were enrolled in this study. It included male and female subjects aged 50-80 years who were required to undergo colonoscopies, voluntarily provide endoscopic imaging and sign an informed consent form.

Who may be able to join

  • Male or female aged 50-80(inclusive) ;
  • Ability to read, understand and sign an informed consent form;
  • The researchers believed that the subjects were able to understand the flow of the clinical study and were willing and able to complete all the procedures and follow-up interviews to accompany the study.

Who cannot join

  • Participants who meet any of the following criteria will be excluded from the study
  • Drug or alcohol abuse or psychological disorders in the last 5 years;
  • Pregnant or lactating women;
  • Patients with known Polyp Syndrome;
  • Patients with known Inflammatory Bowel Disease;
  • Patients with known Intestinal stricture or mass tumor;
Show all 11Show fewer
  • Patients with known colonic obstruction or perforation;
  • Patients with a previous history of colorectal surgery;
  • Patients with a previous history of Anaphylaxis to antispasmodic agents;
  • Blood coagulation disorders or oral anticoagulants and other reasons can not be biopsy and polypectomy;
  • High-risk diseases or other special conditions considered unsuitable for participants in clinical trials.

Trial locations and contacts

1 site in 1 country.

Honggang Yu, Doctoc contact

13871281899

yuhonggang@whu.edu.cn

Liwen Yao, Doctor contact

15827416837

China1 site, 1 recruiting
  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, 430000

    Honggang Yu, Doctor, 13871281899, yuhonggang@whu.edu.cn

    Liwen Yao, Doctor, 15827416837

    Recruiting

Other trials in China

About this study

The quality control index based on artificial intelligence is put forward to monitor the quality of enteroscopy. And we will verify the correlation between the detection rate of adenomas and the percentage of endoscopic overspeed mirrors, the number of times of no-return/successful return, the real-time Bowel preparation provided by EndoAngel. What's more, it is expected that the standard range of quality control index for standard operation of colonoscopy can be proposed according to the detection rate of adenomas.

Read the detailed description

Colonoscopy is a key technique for detection and diagnosis of Lower Gastrointestinal Diseases. High-quality endoscopy leads to better outcomes, However, the skill level of different endoscopists is quite different. The rate of missed diagnosis of colorectal ADENOMAS was 22%, the rate of missed diagnosis ranged from 7.4% to 52.5% . A series of studies showed that 12.1% of patients did not have cancer during colonoscopy but were diagnosed with colorectal cancer (post-colonoscopy Colorectal Cancer, PCCRC) within 5 years, of which 71%-86% could be attributed to the negligence of the endoscopist 6, seven. Therefore, it is very important to improve the quality of routine endoscopic examination while expanding the endoscopic technique.

The quality control index of colonoscope can reflect the operation level of endoscopy doctors, and it is a very important tool to ensure the quality of colonoscope. The examination and feedback of the quality control data of the endoscopist can effectively improve the detection rate of lesions and guarantee the high level of endoscopic quality. It is the key to guarantee the quality of enteroscopy to put forward the quality control index which can reflect the quality of endoscopist operation. Barclay proposed in 2006 that there was a significant correlation between colonoscopy withdrawal time and the rate of Adenomas in patients, and their findings were published in the The New England Journal of Medicine, with an impact factor of 70.67. Then, there were 367 papers on the study of the speed of enteroscopy withdrawal. Aslinia made a retrospective analysis of the correlation between the incidence of blindness reached by enteroscopy and the prognosis of patients, and proposed the incidence of blindness reached as a quality control index for enteroscopy. Other quality control indicators, such as bowel cleanliness and polyp detection rate, have been published in international well-known journals and included in the guidelines to regulate the quality of daily work of endoscopic physicians, which has great clinical significance.

However, despite the above-mentioned quality control indicators, the existing endoscopic quality control indicators are seriously inadequate. According to a multicenter clinical study, current quality control indicators only reflect about 40% of the difference in lesion detection levels between endoscopic physicians. The existence of this phenomenon indicated that more quality control indexes are needed to fully reflect the quality of endoscopic procedures. As a quality control index reflecting intestinal preparation, intestinal cleanliness is a fatal defect with strong subjectivity and poor consistency among observers, therefore, the existing colonoscopy need more comprehensive, objective quality control indicators to reflect the level of endoscopic doctors, so as to ensure the quality of colonoscopy.

In the past decade, artificial intelligence (AI) has made remarkable progress in the medical field. Andre Esteva used a deep neural network (DNN) to classify skin cancer with expert-level accuracy. In the field of digestive endoscopy, the project team in the early is made a huge breakthrough. In 2018, the artificial intelligence gastroscopy blind spot monitoring model developed by the project team significantly reduced the endoscopy blind spot in randomized controlled clinical trials, the findings were published in the journal Gut with an impact factor of 17.94. In 2019, the team's artificial intelligence model for evaluating gut cleanliness, published in the journal gastrogastrotestinal endoscopy with an impact factor of 7.23, showed better picture accuracy than that of the endoscopist in the human computer competition. In the same year, the project developed a model for colonoscopy speed monitoring based on Hasche perception algorithm and a model for colonoscopy slide mirror monitoring based on image classification, and conducted randomized controlled clinical trials, the model significantly improved The ability of colonoscopists to detect lesions, The study was published in The Lancet Gastroenterology 18 with an impact factor of 12.87.

Based on the above-mentioned rich foundation of early work, as well as the current great demand in the field of quality control of enteroscopy, we intend to validate the artificial intelligence-based enteroscopy exit velocity, bowel cleanliness, and enteroscopy slide model developed by the project team through a multi-center clinical study, to evaluate the feasibility and accuracy of doctor's operation quality as a quality control index.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of enteroscopy exit velocity overdrive

    Percentage of enteroscopy exit velocity overdrive

    Measured: 2020.12.2

  2. The adenoma detection rate(ADR)

    ADR was calcilated by dividing the tatal number of patients being detected adenomas by the number of colinoscopies.

    Measured: 2020.12.2

Secondary outcomes (11)
  1. The advanced adenoma detection rate

    The advanced adenoma detection rate was calcilated by dividing the tatal number of patients being detected advanced adenomas by the number of colinoscopies.

    Measured: 2020.12.2

  2. The polyp detection rate(PDR)

    PDR was calcilated by dividing the tatal number of patients being detected polyps by the number of colinoscopies.

    Measured: 2020.12.2

  3. The mean number of adenomas per patient(MAP)

    MAP was calculated by dividing the total number of adenomas by the number of colonoscopies.

    Measured: 2020.12.2

  4. PDR of different size

    It was calculated by dividing the number of patients with polyps that large (≥10mm), small(6-9 mm) and diminutive(≤5 mm) by the number of patients undergoing colonoscopy.

    Measured: 2020.12.2

  5. MNP of different size

    It was calculated by dividing the number of polyps that large (≥10mm), small(6-9 mm) and diminutive(≤5 mm) by the number of patients undergoing colonoscopy.

    Measured: 2020.12.2

  6. ADR of different size

    It was calculated by dividing the number of patients with adenomas that large (≥10mm), small(6-9 mm) and diminutive(≤5 mm) by the number of patients undergoing colonoscopy.

    Measured: 2020.12.2

  7. MAP of different size

    It was calculated by dividing the number of adenomas that large (≥10mm), small(6-9 mm) and diminutive(≤5 mm) by the number of patients undergoing colonoscopy.

    Measured: 2020.12.2

  8. ADR of different location

    It was calculated by dividing the number of patients with adenomas detected in the rectum, sigmoid colon, descending colon, transverse colon, ascending colon, ileocecal region ect. by the total number patients undergoing colonoscopy.

    Measured: 2020.12.2

  9. MAP of different location

    It was calculated by dividing the number of adenomas detected in the rectum, sigmoid colon, descending colon, transverse colon, ascending colon, ileocecal region ect. by the total number patients undergoing colonoscopy.

    Measured: 2020.12.2

  10. Cecal intubation rate

    It was calculated by dividing the number of colonoscopies that get to the ileocecal region by the total number of colonoscopies.

    Measured: 2020.12.2

  11. Cleanliness assessment of different intestinal segment in the artificial intelligence system

    The artificial intelligence evaluates the Boston Bowel Preparation score of the ascending colon, transverse colon,and descending colon in real-time, and calculates the proportion of 1Score.

    Measured: 2020.12.2

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Oct 2020
  2. Study start2 Jun 2020
  3. Primary completion2 Dec 2021 (estimated)
  4. Study completion16 Dec 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
5,813 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04610177
Sponsor's protocol ID
EA-20-003
Status last verified
Jan 2021
First submitted
26 Oct 2020
Last updated
12 Jan 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Individual de-identified participant data that underlie the results reported in this article and study protocol will be shared for investigators whose proposed use of the data has been approved by an independent review committee. Data can only be used to achieve aims in the approved proposal. Data disclosure begins 9 months and ends 36 months after article publication. To gain access, data requesters will need to sign a data access agreement. Proposals should be directed to the corresponding author.

Questions about this trial

What is this clinical trial studying?

An observational study of Quality Evaluation System for Colonoscopy, run by Renmin Hospital of Wuhan University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 12 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Honggang Yu, Doctoc (13871281899, yuhonggang@whu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of enteroscopy exit velocity overdrive (time frame: 2020.12.2). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in